Outlook Therapeutics posts CEO Bob Jahr “Why Now” investor conference webcast on demand
OTLK•Webcast now available on demand
Outlook Therapeutics published an on-demand video webcast of CEO Bob Jahr’s Virtual Investor “Why Now” conference segment here.
- Presentation highlighted FDA approval of LYTENAVA on July 24, 2026 as the only FDA-approved ophthalmic bevacizumab for wet AMD.
- Jahr outlined a shift to commercial-stage operations, citing launch preparations in the U.S. alongside an existing commercial presence in Europe.
- Remarks focused on targeting an established market where bevacizumab is widely used off label, positioning LYTENAVA as a potential standard-of-care change.
